Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 versus pirtobrutinib in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
2025-522860-34-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Dec 2025
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing BGB-16673 with Jaypirca (2 arms). Primary endpoint: Progression-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
catadegbrutinibpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-522860-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522860-34-00.